Eliglustat substrate reduction therapy in children with Gaucher disease type 1
ImportanceGaucher disease (GD) is a rare lysosomal storage disorder with limited treatment options for pediatric patients. Oral substrate reduction therapy (SRT) with eliglustat offers a potential alternative, particularly for those with barriers to enzyme replacement therapy (ERT).ObjectiveEvaluate...
Saved in:
| Main Authors: | Noor Ul Ain, Armaan Saith, Audrey Ruan, Ruhua Yang, Aaron Burton, Pramod K. Mistry |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1543136/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Increased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors
by: Evelina Maines, et al.
Published: (2025-06-01) -
Gaucher's disease - a review of the most important information about the disease in Paediatrics
by: Jakub Jarmołowicz, et al.
Published: (2025-07-01) -
Application of CRISPR/Cas9 technology in the modeling of Gaucher disorder
by: Mehran Reyhani-Ardabili, et al.
Published: (2024-12-01) -
An Overview of Gaucher Disease
by: Daniela Anahí Méndez-Cobián, et al.
Published: (2024-12-01) -
Gaucher’s disease: orphan disease in pediatric practice
by: T. A. Bokova
Published: (2021-06-01)